FHTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Foghorn Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.87+0.02 (+1.08%)
Close on Oct 19, 2026
- Market cap
- $132.08M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
75.6%
45M of 59M shares
Institutional holders
103
15 new, 14 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Bvf Inc/Il | 8,507,000 | 14.30% | 13G (passive) amendment | Oct 1, 2026 |
| FMR LLC | 6,792,356 | 11.60% | 13G (passive) amendment | Mar 31, 2026 |
| Lampert Mark N | 5,866,613 | 9.99% | 13G (passive) amendment | Mar 31, 2026 |
| Deerfield Partners, L.P. | 5,139,523 | 8.64% | 13G (passive) amendment | Mar 31, 2026 |
| Noubar Afeyan | 20,774,885 | 27.20% | 13D (active) amendment | Jan 9, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of FHTX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Flagship Pioneering Inc. | 12,674,120 | 21.34% | $61.85M | – | 4.02% |
| Bvf Inc/Il | 5,842,000 | 9.84% | $28.51M | – | 0.73% |
| FMR LLC | 5,705,958 | 9.61% | $27.85M | −341,240 | 0.00% |
| Deerfield Management Company, L.P. (Series C) | 4,394,367 | 7.40% | $21.44M | – | 0.22% |
| BlackRock, Inc. | 2,626,832 | 4.42% | $12.82M | +261,966 | 0.00% |
| Raymond James Financial Inc | 2,489,978 | 4.19% | $12.15M | −112,404 | 0.00% |
| Euclidean Capital LLC | 1,573,761 | 2.65% | $7.68M | – | 1.75% |
| Vanguard Capital Management LLC | 1,494,611 | 2.52% | $7.29M | −478 | 0.00% |
| Geode Capital Management, LLC | 910,866 | 1.53% | $4.45M | +62,694 | 0.00% |
| Siren, L.L.C. | 720,720 | 1.21% | $3.52M | – | 0.07% |
| State Street Corp | 697,469 | 1.17% | $3.40M | +17,682 | 0.00% |
| Ameriprise Financial Inc | 558,685 | 0.94% | $2.73M | +109,709 | 0.00% |
| Renaissance Technologies LLC | 377,936 | 0.64% | $1.84M | −28,489 | 0.00% |
| Candriam S.C.A. | 313,765 | 0.53% | $1.53M | – | 0.01% |
| Northern Trust Corp | 309,775 | 0.52% | $1.51M | +33,900 | 0.00% |
| Jacobs Levy Equity Management, Inc | 305,434 | 0.51% | $1.49M | +1,677 | 0.01% |
| Vanguard Portfolio Management LLC | 304,432 | 0.51% | $1.49M | +48,501 | 0.00% |
| Birchview Capital, LP | 281,937 | 0.47% | $1.38M | +207 | 0.64% |
| Vanguard Fiduciary Trust Co | 264,422 | 0.45% | $1.29M | +23,836 | 0.00% |
| Qube Research & Technologies Ltd | 203,296 | 0.34% | $992.08K | +122,018 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 103 | 45M | 75.6% | 15 / 40 | 26 / 14 | 1M | 1M |
| Q1 2026 | 105 | 44M | 74.8% | 22 / 40 | 21 / 9 | 5M | 1M |
| Q4 2025 | 93 | 42M | 70.5% | 15 / 30 | 25 / 10 | 2M | 1M |
| Q3 2025 | 88 | 41M | 68.9% | 16 / 27 | 23 / 9 | 1M | 1M |
| Q2 2025 | 81 | 41M | 69.0% | 8 / 37 | 15 / 17 | 1M | 1M |
| Q1 2025 | 90 | 40M | 68.1% | 9 / 26 | 31 / 5 | 1M | 1M |
| Q4 2024 | 87 | 41M | 68.3% | 17 / 32 | 12 / 8 | 3M | 1M |
| Q3 2024 | 79 | 40M | 67.9% | 14 / 28 | 19 / 6 | 4M | 2M |
| Q2 2024 | 72 | 40M | 67.0% | 16 / 23 | 16 / 13 | 13M | 1M |
| Q1 2024 | 69 | 27M | 45.4% | 12 / 19 | 17 / 2 | 1M | 0M |
| Q4 2023 | 59 | 27M | 44.8% | 6 / 19 | 17 / 8 | 2M | 4M |
| Q3 2023 | 61 | 29M | 48.4% | 3 / 17 | 20 / 1 | 2M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of FHTX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Growth Company Fund | 1,836,447 | 3.09% | $7.86M | 0.01% | May 31, 2026 |
| Vanguard Total Stock Market Index Fund | 1,027,071 | 1.73% | $5.01M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 896,556 | 1.51% | $4.38M | 0.01% | Jun 30, 2026 |
| Fidelity Growth Company K6 Fund | 501,007 | 0.84% | $2.14M | 0.01% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 428,310 | 0.72% | $2.09M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 396,371 | 0.67% | $1.80M | 0.01% | Jul 31, 2026 |
| Select Biotechnology Portfolio | 351,578 | 0.59% | $1.50M | 0.03% | May 31, 2026 |
| iShares Russell 2000 Growth ETF | 342,513 | 0.58% | $1.67M | 0.01% | Jun 30, 2026 |
| Fidelity Series Growth Company Fund | 283,912 | 0.48% | $1.22M | 0.00% | May 31, 2026 |
| iShares Biotechnology ETF | 221,798 | 0.37% | $1.08M | 0.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 188,248 | 0.32% | $805.70K | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 175,973 | 0.30% | $753.16K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 122,329 | 0.21% | $596.97K | 0.04% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 87,961 | 0.15% | $398.46K | 0.01% | Jul 31, 2026 |
| Ultra-Small Company Market Fund | 83,000 | 0.14% | $405.04K | 0.27% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Adrian Gottschalk | Chief Executive Officer, Director | 511,704 | 0.86% | Apr 13, 2026 |
| Ryan D. Maynard | Chief Financial Officer | – | – | Feb 24, 2026 |
| Anna Rivkin | Chief Business Officer | – | – | Feb 2, 2026 |
| Michael LaCascia | Chief Legal Officer | – | – | Feb 2, 2026 |
| Alfonso Quintas Cardama | Chief Medical Officer | – | – | Feb 2, 2026 |
| Steven F. Bellon | Chief Scientific Officer | 151,957 | 0.26% | Feb 2, 2026 |
| Carlos Costa | Chief People Officer | 0 | – | Feb 2, 2026 |
| Kristian Humer | Chief Financial Officer | – | – | Nov 17, 2025 |
| Ian F. Smith | Director | 72,072 | 0.12% | Jun 25, 2026 |
| B. Lynne Parshall | Director | – | – | Jun 25, 2026 |
| Douglas G. Cole | Director | – | – | Jun 25, 2026 |
| Scott Biller | Director | – | – | Jun 25, 2026 |
| Thomas J. Lynch Jr. | Director | – | – | Jun 25, 2026 |
| Michael Mendelsohn | Director | – | – | Jun 25, 2026 |
| Simba Gill | Director | 34,061 | 0.06% | Jun 25, 2026 |
| Stuart Duty | Director | – | – | Jun 25, 2026 |
| Neil Gallagher | Director | – | – | Jun 25, 2026 |
| Flagship Pioneering Special Opportunities Fund II, L.P. | Director, 10% owner | – | – | Jan 15, 2026 |
| Ventures Opportunities Fund I. General Partner LLC Flagship | Director, 10% owner | 9,330,878 | 15.71% | Jan 15, 2026 |
| Flagship Pioneering, LLC | Director, 10% owner | – | – | Jan 15, 2026 |
| Flagship Ventures Fund V, L.P. | Director, 10% owner | – | – | Jan 15, 2026 |
| Ventures Fund V. General Partner LLC Flagship | Director, 10% owner | – | – | Jan 15, 2026 |
| Pioneering Fund VII General Partner LLC Flagship | Director, 10% owner | – | – | Jan 15, 2026 |
| Flagship Pioneering Fund VII, L.P. | Director, 10% owner | – | – | Jan 15, 2026 |
| Noubar Afeyan | Director, 10% owner | – | – | Jan 15, 2026 |
| Flagship Ventures Opportunities Fund I, L.P. | Director, 10% owner | – | – | Jan 15, 2026 |
| Pioneering Special Opportunities Fund II General Partner LLC Flagship | Director, 10% owner | – | – | Jan 15, 2026 |
| Adam Koppel | Director | – | – | Dec 30, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Adrian Gottschalk Chief Executive Officer, Director | Apr 10, 2026 | Gift | −59,208 | – | – | 240,792 |
| Adrian Gottschalk Chief Executive Officer, Director | Apr 10, 2026 | Gift | +59,208 | – | – | 270,912 |
| Adrian Gottschalk Chief Executive Officer, Director | Apr 9, 2026 | Gift | +47,497 | – | – | 211,704 |
| Adrian Gottschalk Chief Executive Officer, Director | Apr 9, 2026 | Gift | −47,497 | – | – | 0 |
| Adrian Gottschalk Chief Executive Officer, Director | Apr 25, 2025 | Gift | +300,000 | – | – | 511,704 |
| Adrian Gottschalk Chief Executive Officer, Director | Apr 25, 2025 | Gift | −300,000 | – | – | 511,704 |
| Adrian Gottschalk Chief Executive Officer, Director | Apr 9, 2025 | Gift | +197,906 | – | – | 511,704 |
| Adrian Gottschalk Chief Executive Officer, Director | Apr 9, 2025 | Gift | −197,906 | – | – | 511,704 |
| Carlos Costa Chief People Officer | Sep 23, 2024 | Sale(10b5-1 plan) | −857 | $10.17 | $8.72K | 0 |
| Carlos Costa Chief People Officer | Sep 23, 2024 | Option exercise | +857 | $3.72 | $3.19K | 857 |
| Carlos Costa Chief People Officer | Sep 20, 2024 | Option exercise | +35,756 | $3.72 | $133.01K | 35,756 |
| Carlos Costa Chief People Officer | Sep 20, 2024 | Sale(10b5-1 plan) | −35,756 | $10.04 | $358.99K | 0 |
| Carlos Costa Chief People Officer | Sep 18, 2024 | Sale(10b5-1 plan) | −11,574 | $10.05 | $116.32K | 0 |
| Carlos Costa Chief People Officer | Sep 18, 2024 | Option exercise | +11,574 | $3.72 | $43.06K | 11,574 |
| Carlos Costa Chief People Officer | Sep 17, 2024 | Sale(10b5-1 plan) | −10,272 | $10.04 | $103.13K | 0 |
| Carlos Costa Chief People Officer | Sep 17, 2024 | Option exercise | +10,272 | $3.72 | $38.21K | 10,272 |
| Carlos Costa Chief People Officer | Sep 16, 2024 | Sale(10b5-1 plan) | −400 | $10.00 | $4.00K | 0 |
| Carlos Costa Chief People Officer | Sep 16, 2024 | Option exercise | +400 | $3.72 | $1.49K | 400 |
| Steven F. Bellon Chief Scientific Officer | Sep 9, 2024 | Sale(10b5-1 plan) | −20,000 | $9.50 | $190.00K | 101,957 |
| Fanny Cavalie Chief Strategy/Bus Ops Officer | Mar 11, 2024 | Sale | −11,000 | $6.56 | $72.16K | 75,992 |
| Adrian Gottschalk Chief Executive Officer, Director | Aug 17, 2023 | Gift | −63,000 | – | – | 0 |
| Adrian Gottschalk Chief Executive Officer, Director | Aug 17, 2023 | Gift | +63,000 | – | – | 511,704 |
| Samuel Agresta Chief Medical Officer | Aug 16, 2023 | Sale | −311,297 | $8.25 | $2.57M | 0 |
| Samuel Agresta Chief Medical Officer | Aug 16, 2023 | Option exercise | +311,297 | $3.72 | $1.16M | 311,297 |
| Adrian Gottschalk Chief Executive Officer, Director | May 26, 2023 | Gift | −300,000 | – | – | 448,704 |
| Adrian Gottschalk Chief Executive Officer, Director | May 26, 2023 | Gift | +300,000 | – | – | 448,704 |
| Adrian Gottschalk Chief Executive Officer, Director | Feb 17, 2023 | Gift | −4,371 | – | – | 63,000 |
| Adrian Gottschalk Chief Executive Officer, Director | Feb 17, 2023 | Gift | +4,371 | – | – | 448,704 |
| Adrian Gottschalk Chief Executive Officer, Director | Feb 17, 2023 | Other | −184,939 | – | – | 448,704 |
| Adrian Gottschalk Chief Executive Officer, Director | Feb 17, 2023 | Other | +184,939 | – | – | 448,704 |
| Adrian Gottschalk Chief Executive Officer, Director | Oct 25, 2022 | Other | −4,371 | – | – | 444,333 |
| Adrian Gottschalk Chief Executive Officer, Director | Oct 25, 2022 | Other | +4,371 | – | – | 67,371 |
| Adrian Gottschalk Chief Executive Officer, Director | Sep 16, 2022 | Option exercise | +40,000 | $0.54 | $21.60K | 186,479 |
| Simba Gill Director | Sep 13, 2022 | Gift | −47,939 | – | – | 34,061 |
| Simba Gill Director | Sep 12, 2022 | Option exercise | +82,000 | $0.73 | $59.86K | 82,000 |
| Steven F. Bellon Chief Scientific Officer | Aug 11, 2022 | Option exercise | +1,858 | $3.72 | $6.91K | 121,957 |
| Steven F. Bellon Chief Scientific Officer | May 25, 2022 | Option exercise | +3,717 | $3.72 | $13.83K | 120,099 |
| Steven F. Bellon Chief Scientific Officer | May 25, 2022 | Option exercise | +675 | $0.73 | $493 | 116,382 |
| Adrian Gottschalk Chief Executive Officer, Director | Feb 10, 2022 | Gift | +123,479 | – | – | 448,704 |
| Adrian Gottschalk Chief Executive Officer, Director | Feb 10, 2022 | Gift | −123,479 | – | – | 23,000 |
| Cigall Kadoch Director, 10% owner | Dec 14, 2021 | Gift | −333,333 | – | – | 295,000 |
| Carl Decicco Chief Scientific Officer | Dec 9, 2021 | Option exercise | +104,310 | $3.72 | $388.03K | 362,707 |
| Adrian Gottschalk Chief Executive Officer, Director | Aug 20, 2021 | Option exercise | +23,000 | $0.54 | $12.42K | 446,479 |
| Allan Reine Chief Financial Officer | Aug 9, 2021 | Option exercise | +26,892 | $3.72 | $100.04K | 53,784 |
| Carl Decicco Chief Scientific Officer | Oct 27, 2020 | Buy | +5,500 | $16.00 | $88.00K | 258,397 |
| Adrian Gottschalk See Remarks, Director | Oct 27, 2020 | Conversion | +25,225 | – | – | 25,225 |
| Ventures Opportunities Fund I. General Partner LLC Flagship 10% owner | Oct 27, 2020 | Buy | +50,000 | $16.00 | $800.00K | 9,330,878 |
| Ventures Opportunities Fund I. General Partner LLC Flagship 10% owner | Oct 27, 2020 | Conversion | +4,504,504 | – | – | 8,558,558 |
| Ventures Opportunities Fund I. General Partner LLC Flagship 10% owner | Oct 27, 2020 | Conversion | +4,054,054 | – | – | 4,054,054 |
| Ventures Opportunities Fund I. General Partner LLC Flagship 10% owner | Oct 27, 2020 | Conversion | +1,441,441 | – | – | 1,441,441 |
| Ventures Opportunities Fund I. General Partner LLC Flagship 10% owner | Oct 27, 2020 | Buy | +50,000 | $16.00 | $800.00K | 1,491,441 |
| Ventures Opportunities Fund I. General Partner LLC Flagship 10% owner | Oct 27, 2020 | Conversion | +722,320 | – | – | 9,280,878 |
| Ventures Opportunities Fund I. General Partner LLC Flagship 10% owner | Oct 27, 2020 | Conversion | +1,801,801 | – | – | 1,801,801 |
| Ventures Opportunities Fund I. General Partner LLC Flagship 10% owner | Oct 27, 2020 | Buy | +50,000 | $16.00 | $800.00K | 1,851,801 |
| Dhabi Investment Authority Abu – | Oct 27, 2020 | Buy | +150,000 | $16.00 | $2.40M | 1,231,081 |
| Dhabi Investment Authority Abu – | Oct 27, 2020 | Conversion | +1,081,081 | – | – | 1,081,081 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Costa Carlos Officer | Sep 16, 2024 | 98,648 | $958.86K | Sep 16, 2024 | Exercise of Stock Options |
| Bellon Steven Officer | Sep 9, 2024 | 20,000 | $150.60K | Sep 9, 2024 | Previously Exercised Options |
| Agresta Samuel Officer | Aug 16, 2023 | 311,297 | $2.57M | Aug 16, 2023 | Exercise of options under a registered plan |